NDI 101150
Alternative Names: NDI-101150; NMBS-2Latest Information Update: 13 Jun 2024
At a glance
- Originator Nimbus Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Hematopoietic progenitor kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 13 Jun 2024 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 31 May 2024 Adverse events and pharmacokinetics data from the phase I/IIa trial in Solid tumours presented at 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 23 May 2024 Efficacy data from the phase I/II trial in solid tumors released by Nimbus Therapeutics